GLAXOSMITHKLINE'S marketing practices in China have come under scrutiny by the China Food and Drug Administration which has announced a six-month probe covering issues such as bribery, authorised medicine sales, counterfeit drugs and forged receipts.
The rumour mill hints at four companies being implicated although this is not yet confirmed.
Analysts consider the investigation may have some negative effect on GSK's reputation, but probably not impact on its top line performance.
The above article was sent to subscribers in Pharmacy Daily's issue from 14 Jan 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Jan 19